Bacterial Infections

Wingard, John R.; Leather, Helen

doi:10.1002/9780470987070.ch51

Cited by 13 publications

(16 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The markedly elevated risk of infection associated with mTBI use is likely to result from mucosal breaches allowing microbial invasion, and the delayed immune reconstitution associated with mTBI. 18,19 This is consistent with the observation that the majority of infective episodes were bacteremic episodes, which may have resulted from egress of pathogens from the gut across damaged mucosae to the circulation. Notably, mTBI resulted in significant increases in MBL levels during the peritransplantation period, but only in individuals lacking MBL2 coding mutations.…”

Section: Discussionsupporting

confidence: 88%

Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation

Mullighan

Heatley

Danner

et al. 2008

Blood

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 88%

Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation

Mullighan

Heatley

Danner

et al. 2008

Blood

View full text Add to dashboard Cite

show abstract

“…Prophylactic drugs against GVHD typically continue to day 80 after transplantation after myeloablative conditioning regimens but may be tapered earlier than this after nonmyeloablative conditioning to promote a graft-versus-tumor effect. Prophylaxis for infections includes acyclovir for patients who are seropositive for herpes simplex virus, trimethoprim/sulfamethoxazole to prevent Pneumocystic jiroveci infection, oral fluconazole for prophylaxis of candidal infection, and preemptive ganciclovir for cytomegalovirus disease among viremic patients (5)(6)(7)(8).…”

Section: Technique Of Hctmentioning

confidence: 99%

Chronic Kidney Disease in Long-Term Survivors of Hematopoietic Cell Transplantation

Hingorani

2006

Journal of the American Society of Nephrology

128

111

View full text Add to dashboard Cite

High-dose myeloablative hematopoietic cell transplantation is becoming an increasingly common treatment modality for a variety of diseases. Patient survival may be limited by substantial treatment-related toxicities, including chronic kidney disease (CKD). Although the majority of CKD after transplantation is idiopathic, thrombotic microangiopathic syndromes and nephrotic syndrome have been described. Epidemiology, pathogenesis, and potential treatment options for the various clinical syndromes that are associated with CKD in hematopoietic cell transplantation patients is reviewed. As the indications for and the numbers of transplants that are performed worldwide increases, so will the burden of CKD. The nephrologists and oncologists will have to work together to identify patients who are at risk for CKD early to prevent its development and progression to end-stage kidney disease. 17: 199517: -200517: , 200617: . doi: 10.1681 H igh-dose myeloablative therapy followed by hematopoietic cell transplantation (HCT) is an increasingly common treatment for many malignancies and some genetic disorders. Approximately 20,000 HCTs now are performed annually worldwide and offer the prospect of cures for otherwise fatal or incurable diseases. The indications and applications for HCT are growing; for example, HCT now is considered for treatment of autoimmune diseases, Crohn's disease, and vasculitides that are refractory to other therapies (1,2). However, patient survival may be limited by substantial treatment-related toxicities. J Am Soc NephrolThis review focuses on chronic kidney disease (CKD) in survivors of HCT. For the nephrology consultant who deals with transplant survivors, it is important to be aware of the specific type of transplant and its complications to determine how best to treat the patient with renal injury secondary to thrombotic microangiopathy (TMA) syndromes, nephrotic syndrome (NS), persistent acute renal failure (ARF), and idiopathic CKD. Technique of HCTEach type of transplant carries its own risks and toxicities (Table 1). Autologous transplants involve the harvesting of a patient's own bone marrow or peripheral blood stem cells before high-dose myeloablative therapy, followed by re-infusion. Allogeneic transplants use bone marrow or peripheral blood stem cells from family members (ideally, HLA-matched siblings) or HLAmatched unrelated donors or stem cells from umbilical cord blood.Syngeneic transplants are from an identical twin donor. The infusion of stem cells is preceded by either myeloablative therapy (usually a combination of chemotherapy drugs or chemotherapy plus total body irradiation [TBI]) or nonmyeloablative (but immunosuppressive) therapy that allows host hematopoietic cells to coexist with donor stem cells to achieve mixed hematopoietic cell chimerism. The components of both myeloablative and nonmyeloablative conditioning regimens vary from center to center. The most common myeloablative regimens are cyclophosphamide plus TBI 10 to 14 Gy, busulfan plus cyclophosphamide, and busulf...

show abstract

“…2 Techniques of GVHD and microbial prophylaxis have changed over the 27 years encompassed by this report. [3][4][5] Patients are followed by our respective centers to day 100 and then by their local physicians.…”

Section: Techniques Of Hematopoietic Cell Transplantationmentioning

confidence: 99%

Biliary obstruction in hematopoietic cell transplant recipients: an uncommon diagnosis with specific causes

Murakami

Louie

Chan

et al. 1999

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Jaundice is a common problem in marrow transplant recipients. The incidence of bile duct obstruction in this setting is unknown. The purpose of this study was to determine the incidence of biliary obstruction, the causes, and outcomes following marrow transplant. Consecutive cases were reviewed at two major transplant centers in the United States from 1969 to 1996 at the Fred Hutchinson Cancer Research Center and 1989 to 1996 at the City of Hope National Medical Center. Nine cases of biliary obstruction were identified as a cause of jaundice in 7412 marrow transplant recipients, an incidence of 0.12%. The presentation was bimodal, with seven cases occurring prior to day 100 and two occurring 2 to 4 years after transplantation. The age distribution was 15 to 50 years and all patients had received allogeneic transplants. The causes of obstruction included gallbladder sludge (n‫,)1؍‬ a duodenal hematoma (n‫,)1؍‬ choledocholithiasis with biliary pancreatitis (n‫,)1؍‬ bile duct infection (n‫,)2؍‬ recurrent malignancy (n‫,)1؍‬ choledocholithiasis associated with a benign stricture (n‫,)1؍‬ Epstein-Barr virus-related lymphoproliferative disorder (n‫,)1؍‬ and a benign stricture of unknown etiology (n‫.)1؍‬ Biliary obstruction is a rare cause of jaundice in the post-transplant period. The presentation was similar to that of other post-transplant hepatobiliary problems, but with disparate causes.

show abstract

Bacterial Infections

Cited by 13 publications

References 155 publications

Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation

Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation

Chronic Kidney Disease in Long-Term Survivors of Hematopoietic Cell Transplantation

Biliary obstruction in hematopoietic cell transplant recipients: an uncommon diagnosis with specific causes

Contact Info

Product

Resources

About